Procter & Gamble Health recently announced its financial results for the quarter and fiscal year ending 30th June, 2022. In a year impacted by macroeconomic challenges, the company recorded sales of Rs 1,092 crore for the fiscal year ending 30th June, 2022, up by 10 per cent vs year ago supported by strong established brands in healthcare space trusted by healthcare professionals. The Profit After Tax (PAT) for the year ending 30th June, 2022 is Rs 193 crores, up by nine per cent, despite unprecedented commodity inflations during this fiscal, a statement from the company said.
The company has recorded a strong performance with sales of Rs 289 crore in the quarter ending 30th June, up by three per cent vs year ago. Domestic sales were up by eight per cent; however, quarter performance was impacted by economic and financial challenges in Sri Lanka, added the statement.
In addition to it, the statement mentioned that the Board of Directors have recommended a final dividend of Rs 11.50 per equity share, for the financial year ending 30th June, 2022. Considering interim dividend of Rs 41 per share, total dividend payout for the fiscal will be Rs 52.50 per share, subject to the approval of final dividend by shareholders of the company at the ensuing 55th Annual General Meeting.
fantastic blog!